-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gastroesophedic reflow disease is a common combination of idynic pulmonary fibrosis (IPF) that may promote its progress.
such as proton pump inhibitors (PPI) have been seen as potential treatments for IPF.
a recent study published in the authoritative journal Chest in the field of respiratory medicine, which aims to clarify whether the use of PPI treatment in IF patients reduces all-cause mortality, respiratory-related mortality and respiratory-related hospitalizations.
used the UK Clinical Practice Study data chain to determine the queue of patients diagnosed with IF between 2003 and 2016.
used the Cox model to estimate the risk ratio (HR) and 95% confidence interval (CI) for death and respiratory-related hospitalizations, and to correct the information review with a weighted inverse probability.
in the IF patient queue, there were 1,852 PPI users and 1,852 matching non-users with a medium survival of 2.8 years (26.7 per 100 patients per year).
compared to those who did not take PPI, the HR mortality rate for PPI takers was 1.07 (95% CI was 0.94-1.22).
HR for respiratory-related mortality was 1.10 (95% CI was 0.94-1.28) and HR for respiratory-related hospitalization was 1.00 (95% CI was 0.86-1.16).
, in this large study of IPAF patients, PPI was not associated with lower mortality or hospitalization rates.
benefits of taking PPI may not be as effective as some studies recommend.
.